QTRH tomorrowYahoo Finance shows only one analyst with numbers for QTRH Q2 - topline and EPS estimates. which I've used below. The spreadsheet below allocates the in-between numbers, based on prior quarters MD&A. Corporate cost were distributed to the operating divisions in the Q1 release, but not in Q4-22. Thus, Q3-22 corporate costs include costs that should be allocated to Wilan. For ITS direct cost of goods I used the average for the past 3 quarters of 78.2%; the 3-quarter range was 86.7% to 72.7%, do there is the possibility of both upside and downside.
It is reasonable to expect higher revenue, but the analysts forcast is ~+18% versus the prior 3-quarter average. Q2 is traditionally a solid quarter for IRD and some ETC projects are moving closer to exiting th implementation phase, which should bump unbilled work.
Let's see how close this estimate comes to actual.
| QTRH ITS | | | | |
| | | | | |
| | | | | |
| Corp Fiscal | Q2-23 Fcst | Q2-23 Act | Q1-23 | Q4-22 |
| Total Revenue | $47,300 | | $38,315 | $40,142 |
| | | | | |
| Cost of Revenue | $37,000 | | $33,237 | $29,976 |
| | | | | |
| Gross Profit | $10,300 | $0 | $5,078 | $10,166 |
| | | | | |
| Margin | 21.8% | #DIV/0! | 13.3% | 25.3% |
| | | | | |
| Selling/General Admin | $10,000 | | $9,405 | $9,443 |
| R&D | $1,200 | | $1,175 | $586 |
| Other | $1,000 | | $1,303 | $4,036 |
| TOTAL Cash Expenses | $12,200 | $0 | $11,883 | $14,065 |
| | | | | |
| EBITDA | -$1,900 | $0 | -$6,805 | -$3,899 |
| | | | | |
| EBITDA Percent | -4.0% | 0.0% | -17.8% | -9.7% |
| | | | | |
| Interest/Depreciation/Amortization | $5,700 | | $5,865 | $3,976 |
| Corporate | | | | $4,923 |
| | | | | |
| Operating Income | -$7,600 | $0 | -$12,670 | -$12,798 |
| | | | | |
| Operating Income Percent | -16.1% | #DIV/0! | -33.1% | -31.9% |
| | | | | |
| Shares OOS (000s) | 114,640 | | 114,640 | 114,640 |
| | | | | |
| EPS | -$0.07 | | -$0.11 | -$0.11 |
| | | | | |